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Abstract: Gut-derived serotonin (5-HT) is released from enterochromaffin (EC) cells in response
to nutrient cues, and acts to slow gastric emptying and modulate gastric motility. Rodent studies
also evidence a role for gut-derived 5-HT in the control of hepatic glucose production, lipolysis and
thermogenesis, and in mediating diet-induced obesity. EC cell number and 5-HT content is increased
in the small intestine of obese rodents and human, however, it is unknown whether EC cells respond
directly to glucose in humans, and whether their capacity to release 5-HT is perturbed in obesity.
We therefore investigated 5-HT release from human duodenal and colonic EC cells in response to
glucose, sucrose, fructose and α-glucoside (αMG) in relation to body mass index (BMI). EC cells
released 5-HT only in response to 100 and 300 mM glucose (duodenum) and 300 mM glucose (colon),
independently of osmolarity. Duodenal, but not colonic, EC cells also released 5-HT in response to
sucrose and αMG, but did not respond to fructose. 5-HT content was similar in all EC cells in males,
and colonic EC cells in females, but 3 to 4-fold higher in duodenal EC cells from overweight females
(p < 0.05 compared to lean, obese). Glucose-evoked 5-HT release was 3-fold higher in the duodenum
of overweight females (p < 0.05, compared to obese), but absent here in overweight males. Our data
demonstrate that primary human EC cells respond directly to dietary glucose cues, with regional
differences in selectivity for other sugars. Augmented glucose-evoked 5-HT release from duodenal
EC is a feature of overweight females, and may be an early determinant of obesity.
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1. Introduction
Serotonin (5-hydroxytryptamine; 5-HT) is a monoamine produced from the hydroxylation of
the dietary amino acid L-tryptophan via the rate-limiting actions of tryptophan hydroxylase (TPH).
In vertebrates, two isoforms of TPH are encoded by the genes TPH1 and TPH2, and give rise to
independent pools of 5-HT. TPH1 is expressed in the periphery, largely in enterochromaffin (EC) cells
of the gastrointestinal (GI) tract [1,2] where the majority (~90%) of total body 5-HT is produced [3].
TPH2 is expressed largely in neurons of the myenteric plexus, and centrally in the Raphe nuclei of
the brainstem [2]. Gut-derived 5-HT enters the circulation and is primarily sequestered in platelets.
However, free (extracellular) 5-HT can be transported into cells expressing the serotonin transporter
(SERT). In the liver, this reuptake precedes breakdown of 5-HT to the metabolite 5-hydroxyindoleacetic
acid (5-HIAA), which is then excreted via the kidney.
EC cells express a repertoire of receptors for sweet and bitter tastants, amino acids, fatty acids
and bile acids, as well as transporters for nutrient absorption [4–6]. EC cells are also stimulated by
short-chain fatty acids and secondary bile acids produced by gut microbiota [7] and by mechanical
stimulation [8,9]. Glucose has been shown to directly trigger 5-HT release from isolated primary EC
cells from guinea-pigs and mice [10,11], as well as from the intact rodent gut [12]. 5-HT released
from the gut serves pleiotropic roles, including as a paracrine modulator of colonic motility [8,13,14],
and activator of vagal afferent 5HT3 receptors to slow gastric emptying to optimise digestion and
absorption of nutrients [15]. Other roles in the periphery include regulation of GI secretory responses,
platelet aggregation and immune function [16–18], while centrally, 5-HT serves as a well-described
neurotransmitter for mood, sleep, pain perception and appetite control [19]. Fasting also increases gut
Tph1 gene expression and plasma 5-HT levels in mice, which mobilises energy stores via stimulation of
gluconeogenesis and lipolysis in hepatocytes and adipocytes, respectively, via 5-HTR2B receptors [20].
Gut-derived 5-HT has recently emerged as a mediator of obesogenic processes. Plasma 5-HT and
EC numbers in the proximal intestine are increased in rodent and human models of obesity, and in
rodents this has been shown to occur ahead of weight gain [21–24], while genetic or pharmacological
inhibition of TPH protects against diet-induced obesity and dysglycaemia in mouse models of obesity.
This protection against obesity is in large part due to the attenuation of 5-HT-dependent inhibition of
energy expenditure via adaptive thermogenesis [20,25].
While regional differences in nutrient sensing capability have been reported in EC cells in mice [11],
there are no equivalent data in humans. Furthermore, it is unknown whether glucose-evoked 5-HT
secretion from human EC cells differs between health and obesity, or between male and female subjects.
In this study, we isolated EC cells from the duodenum and colon of non-obese and obese subjects to
investigate sugar-dependent activation. We determined ex vivo EC cell responses to euglycemic (5 mM
glucose), hyperglycemic (30 mM) and meal-related luminal glucose concentrations (100 mM, 300 mM),
and responses to sucrose, fructose, α-methyl-D-glucopyranoside (αMG) and mannitol. We show that
EC-5-HT secretion is dose-dependent at meal-related glucose concentrations, and that there were
regional differences in EC cell glucose sensing and sugar selectivity. Finally, we show that 5-HT outputs
from duodenum are augmented in overweight females, which may represent a sex-specific driver
of obesity.
2. Materials and Methods
2.1. Subjects
For duodenal tissues, subjects aged ≥ 18 years were recruited from patients undergoing an
endoscopic investigation of the upper gastrointestinal tract at the Royal Adelaide Hospital (RAH).
Subjects fasted for endoscopy overnight, and had an intravenous cannula inserted into a forearm
vein for administration of intravenous sedation (midazolam and fentanyl) prior to the procedure.
Upper GI endoscopy (GIF-H180, Olympus, Tokyo, Japan) was performed to the second part of the
duodenum, from which mucosal biopsies were collected using standard biopsy forceps. For colonic
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tissue, morphologically normal colonic tissue specimens were collected from patients undergoing
bowel resections for cancer or stoma reversal at the Flinders Medical Centre and Flinders Private
Hospital. Subjects who were pregnant, or who were receiving drugs known to alter gastrointestinal
function were excluded from the study. Subjects were also excluded if mucosal abnormalities were
detected at endoscopy or colon dissection. Study protocols were approved by the Human Research
Ethics Committees of the RAH (131119), Flinders Medical Centre and Flinders Private Hospital
(EC00188) and conducted in accordance with the Declaration of Helsinki, as revised in 2000. Written
informed consent was obtained from all participants.
2.2. Cell Isolation
Duodenal and colonic tissue samples were collected into modified N-2-hydroxyethylpiperazine-
N′-2-ethanesulfonic acid (HEPES) buffer (containing, in mM: 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2,
10 HEPES, 5 Glucose, pH 7.4). EC cells were isolated from duodenal and colonic tissue as
described [24,26]. For colon samples, mucosa was scraped from ~2cm2 of resected colon. Minced
colonic mucosa and duodenal biopsies were digested for 45 min (duodenum) or 1 h (colon), prior to
filtration and separation using a 10-step Percoll density gradient (density (d) = 1.024 to 1.123 g/mL)
(GE Healthcare). Cells were harvested from the consecutive Percoll layers 1.047, 1.059 and 1.07 g/mL
(cell density 1.047 g/mL < d < 1.082 g/mL), washed in growth medium, and incubated in fresh
growth medium at 37 ◦C, 5% CO2 for between 1 and 2 h, until commencement of the secretion assay.
Preparations of >90% EC cells (5-HT positive) are typically obtained using this method [10,11,24,26].
2.3. Secretion Assay, 5-HT Content and Sensitivity Measurements
Following isolation, cell counts, and viability were assessed using a hemocytometer and Trypan
blue dye exclusion. Cells were centrifuged at 700× g for 5 min, the supernatant discarded, and cells
washed and resuspended in Krebs containing 1uM fluoxetine (SERT inhibitor) and 5-HT stabilisation
buffer (Labor Diagnostika Nord (LDN), Nordhorn, Germany) and pH adjusted prior to the assay.
120 µL of cell suspension (2.5 × 104 viable cells) was placed in wells of a 96-well plate, and incubated
at 37 ◦C with 5% CO2 for 30 min, to allow the cells to adhere and equilibrate. For secretion
experiments, 60 µL was collected from each well and 3 of these samples stored to determine the
average pre-treatment baseline 5-HT concentration. Care was taken at all stages to minimise mechanical
stimulation of the EC cells. For response testing, 60 µL of treatment (in Krebs + 1µM fluoxetine (Sigma
Aldrich, St. Louis, Missouri, USA) + 5-HT stabiliser (LDN, Nordhorn, Germany), pH 7.4) was added
to each well to achieve the desired assay concentration for each sugar, and the cells were incubated
for 20 min at 37 ◦C in 5% CO2. D-glucose, sucrose, methyl α-D-glucopyranoside (αMG), D-fructose,
and D-mannitol were purchased from Sigma Aldrich, St. Louis, Missouri, USA. 80µL was then
collected and stored at −20◦C. From the 5-HT ELISA data, net 5-HT secretion was calculated by
subtracting the average baseline reading from each final reading.
For total 5-HT content measurements, cells were lysed after equilibration by replacing 110 µL
Krebs with 110 µL of deionised H2O (containing a 1x 5-HT stabiliser (LDN, Germany), pH 7.4).
A sample of 80 µL was collected after 20 min and stored at −20◦C. 5-HT in cell secretions and EC cell
lysates was determined by enzyme-linked immunosorbent assay (BAE-5900 Labor Diagnostika Nord,
Nordhorn, Germany) and expressed in nM (2.5 × 104 cells per 120µL).
As a measure of EC sensitivity to glucose, the glucose-evoked 5-HT output:content ratio was
calculated as the ratio of net secretion of 5-HT in 20 min exposure to 300 mM glucose to cellular 5-HT
content in a parallel sample of cells at the zero timepoint.
2.4. Statistics
Statistical analysis was performed using Prism software (version 6; GraphPad, La Jolla, CA, USA).
Sugar-dependent 5-HT outputs (Figures 1–3) for each sex/BMI/gut region group were analysed using
a paired one-way analysis of variance (ANOVA) with Tukey’s post-hoc test. To compare 5-HT content
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(Figure 4) and 300 mM glucose-evoked 5-HT release (Figure 3) considering BMI and sex as factors,
a two-way ANOVA was used, with a Holm-Sidak’s post-hoc test. An unpaired 1-way ANOVA with
Tukey’s post hoc test was used to compare glucose sensitivity for each sex and within each gut region
(Figure 5). Data represents mean +/− SEM; Probability (p) values < 0.05 were considered significant.
3. Results
3.1. EC Cell Responses to Extracellular Glucose
EC cells from non-obese subjects (BMI < 30 kg/m2) were used to investigate 5-HT glucose-evoked
responses (Demographics, Table 1). EC cells were exposed to euglycemic 5 mM (control),
hyperglycaemic 30 mM, and meal-related (luminal) 100 mM or 300 mM glucose concentrations
for 20 min, and glucose-evoked 5-HT release determined. Duodenal EC cells released 5-HT in
a dose-dependent manner at meal-related 100 mM (p < 0.05) and 300 mM glucose concentrations
(p < 0.01), while 5-HT was released from colonic EC cells at 300 mM glucose (p < 0.001, Figure 1).
No significant response was observed in 30 mM glucose (Figure 1).
Table 1. Demographics for glucose dose response in non-obese individuals for data shown in Figure 1.
Duodenum Colon
n 15 17
BMI (kg/m2) 24.9 ± 0.9 25.0 ± 0.9
Age (years) 50.2 ± 5.4 69.6 ± 4.4
M:F 10:5 6:11
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Figure 1. Human enterochromaffin (EC) cells respond to meal-related glucose concentration. Glucose-
evoked 5-HT release from EC cells from human duodenum (a) and colon (b) is dose dependent in 
response to meal-related (luminal) glucose concentrations. Paired data shown for duodenum (N = 15) 
and colon (N = 17). * p < 0.05; ** p < 0.01, *** p < 0.001. 

















Figure 1. Human enterochromaffin (EC) cells respond to meal-related glucose concentration.
Glucose-evoked 5-HT release from EC cells from human duodenum (a) and colon (b) is dose dependent
in response to meal-related (luminal) glucose concentrations. Paire data shown for duodenum (N = 15)
and colon (N = 17). * p < 0.05; ** p < 0.01, *** p < 0.001.
3.2. EC Cell Responses to Other Extracellular Sugars
The regional and nutrient-sensing repertoire of EC cells were determined in paired comparisons of
5-HT outputs in response to 300 mM glucose and equimolar mannitol (non-absorbable hexose, osmotic
control), α-methyl-D-glucopyranoside (αMG; an absorbable, but non-metabolised, sugar derived from
glucose), fructose and sucrose (Figure 2A–D). The release of 5-HT from duodenal and colonic EC cells
did not occur in response to 300 mM mannitol (Figure 2A). Duodenal EC cells increased 5-HT release
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in response to 300 mM glucose (p < 0.05), αMG (p < 0.05) and sucrose (p < 0.01). In contrast, colonic EC
cells released 5-HT only in response to glucose (p <0.01).
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Figure 2. EC cell responses t l t er sugars. Release of 5-HT from duodenal and col nic EC
cells in response to 300 mM glucose and equimolar (a) mannitol (N = 7 duo enum, 6 colon), (b) αMG
(N = 5 duodenum, 9 colon), (c) fructose (N = 6 duodenum, 6 colon), and (d) sucrose (N = 7 duodenum,
6 colon). * represents significant differences compar d t 5mM glucose, # represents significant
differences compar d t 300mM glucose; p < 0.05 (*, #), p < 0.01 (**, ##).
3.3. Sex and BMI Related Effects on EC 5-HT Content
We assessed whether EC cell 5-HT content was related to sex or BMI category in lean
(BMI < 25 kg/m2), overweight (25 kg/m2 ≤ BMI < 30 kg/m2) or obese (BMI ≥ 30 kg/m2) subjects
(Demographics, Table S1). Duodenal EC cells from overweight females had > 3-fold higher 5-HT
content (6.5 ± 1.0 nM) than EC cells from either lean or obese females (1.3 ± 0.2 nM; 2.0 ± 0.3 nM
respectively; both p < 0.001), and ~2.6-fold higher levels than overweight males (2.5 ± 0.8 nM; p < 0.05).
In contrast, EC cell 5-HT content was unrelated to BMI in males, and was similar in colonic EC cells for
both sexes (Figure 3).
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3.4. Sex and BMI Related Effects on Glucose-Evoked 5-HT Release.
Glucose-evoked 5-HT release from EC cells in lean, overweight and obese subjects at euglycemia
(5 mM glucose), and at meal-related glucose concentrations (100 mM, 300 mM), were compared in
duodenum and colon (Demographics, Table S2). 5-HT release from duodenal and colonic EC cells was
similar across lean, overweight and obese subjects, and sexes, at 5 mM glucose, and was augmented at
300 mM glucose in duodenum and colon in all groups relative to euglycemic lean (p < 0.05), except
in the duodenum of overweight males (Figure 4). At 300 mM glucose, EC cell 5-HT outputs were
3-fold higher in the duodenum of overweight (3.5 ± 0.7 nM) compared to obese females (1.4 ± 0.3 nM;
p < 0.05), and 4-fold higher than overweight males (0.8 ± 0.2 nM).
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Figure 4. 5-HT content is increased only in duodenal EC cells from overweight females. Comparison
of the 5-HT content in EC cells by sex, BMI category, and gut region. The number of patients in each
group (N) is shown under each bar. * and # represent significant differences in the duodenum, in a
two-way ANOVA considering sex and BMI category with Holm-Sidak’s multiple comparison test.
* represents significant differences between BMI categories; # represents significant differences between
sexes. p < 0.01 (**, ##).
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3.5. Sex and BMI Related Effects on EC Cell Glucose Sensitivity
To investigate whether BMI-associated differences in glucose-evoked 5-HT output were related to
altered glucose sensitivity, the ratio of 300mM glucose-evoked 5-HT released (in 20 min) to cellular
5-HT content (at time = 0) was calculated (Figure 5; Demographics, Table S3). A decrease in 5-HT
output:content ratio was evident in EC cells from the duodenum of female subjects for both overweight
(0.5 ± 0.1; p < 0.01) and obese (0.6 ± 0.2; p < 0.05) groups compared to the lean group (1.6 ± 0.3).
This suggests that decreased glucose sensitivity accompanies the increased 5-HT synthesis (content)
in the overweight group (Figure 3). No difference in output:content ratio was observed between the
female overweight and obese groups. EC cells from lean female duodenum showed more release
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per content than those from lean male duodenum (0.5 ± 0.1 nM). No BMI-associated differences
in output:content ratio were observed in colonic EC cells or duodenal EC cells from male subjects
(Figure 5).
4. Discussion
This study is the first to describe a dose and glucose-dependent release of 5-HT from primary
human EC cells in response to meal-related luminal glucose concentrations. We also showed that
this response does not occur at a high post-prandial blood glucose concentration. We found that
5-HT release from duodenal EC cells was augmented, and more broadly tuned to sugars, than
from colonic EC cells. All outputs were sugar-specific, and not triggered by iso-osmotic mannitol.
Finally, we showed that duodenal EC cells from overweight female subjects had higher 5-HT content
compared to lean and obese female subjects, and greater glucose-evoked 5-HT secretion than those
from obese females. Furthermore, 5-HT content and glucose-evoked secretion were greater in EC
cells from overweight females than from overweight males. Comparing the findings of this study
with previous studies reveals similarities and differences in EC cell glucose sensing biology across
species, and according to gut location. The finding that human EC cells release 5-HT in response only
to luminal (and not serum) glucose concentrations is consistent with past investigations from our
group, in guinea pig [10] and mouse [6]. However, although cross-species similarities in EC sugar
selectivity were apparent between mouse and human, only human duodenal EC cells respond to αMG,
while only mouse EC cells respond to fructose [11]. This highlights a broad range of glucose-sensing
mechanisms in EC cells, which are specific to gut location and species.
We show that duodenal and colonic EC cells respond to high glucose in humans, but with a
broader repertoire of sugar sensing in the former. In vivo, these gut regions experience different
luminal products and carbohydrate concentrations. The duodenum, like other small intestine regions,
is tuned to dietary carbohydrate absorption, in contrast to the colon. The colon is unlikely to experience
high glucose concentrations except in the setting of incomplete small intestine absorption, such as in
rapid intestinal transit due to disease, or following resective surgery. Moreover, regional differences in
nutrient receptor expression that may subserve these distinct sensing repertoires have been reported in
mouse and human small and large intestine [5], and in isolated primary EC cells isolated from mouse
duodenum and colon [11].
We observed the sucrose-dependent release of 5-HT in human duodenum. Sucrose is a putative
ligand for the sweet taste receptor (comprised of T1R2 and T1R3 subunits), which is localised only
to the small intestine in the gut of mice and humans [5]. The lack of response to fructose, however,
argues against a major involvement of sweet taste receptors in the sugar sensing repertoire of human
EC cells. This is in contrast to our earlier findings of duodenum-specific and fructose-dependent 5-HT
release, and enrichment of T1R3 transcripts, in EC cells from mouse duodenum [6,11] where sweet taste
receptors are likely to be involved in sugar sensing. An alternative possibility in humans is that the
sucrose response is mediated by monosaccharide glucose liberated by the actions of disaccharidases
present in the brush border membrane of the small intestine.
The release of 5-HT from human duodenal EC cells in response to the glucose analogue αMG
indicates that glucose metabolism is not required to trigger 5-HT release from human duodenal EC cells.
Glucose and αMG are substrates of the sodium-glucose co-transporter family of glucose transporters
(such as SGLT1), and sensors (SGLT3), that are abundantly expressed in the proximal intestine [27,28].
The selectivity of human duodenal EC cells for glucose and αMG, but not fructose, is similar to
that of BON cells [29], a serotonergic human cell line derived from a pancreatic neuroendocrine
tumour, in which SGLT1 is an identified glucose sensor [29]. Indeed, SGLT1 transcripts are present
in EC cells from mouse and human [4,6], while SGLT1-dependent glucose transport in proximal
(but not distal) L-cells triggers a glucose-dependent release of the incretin, glucagon-like peptide 1
(GLP-1) [30]. SGLT3 has also been proposed as a candidate glucose sensor in EC cells. This is based on
evidence from rodent studies that 5-HT is released into the mesenteric lymph in response to glucose,
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but not galactose (an SGLT-1 selective substrate), and that EC cells are activated directly by the SGLT3
agonist, deoxynojirimycin [31,32]. However, the exact glucose sensor(s) in human EC cells remain to
be identified.
While SGLTs have the potential to trigger glucose-evoked 5-HT release in proximal EC cells in
humans, the lack of response of colonic EC cells to αMG (and previously, in mice) suggests against the
involvement of SGLTs in the colon. While nutrient sensing in human EC cells has been investigated
in EC cells of the proximal intestine [33], and pancreas-derived BON cells (which have proximal
intestine-like properties with regards to sugar selectivity), our study is the first to report glucose-evoked
5-HT release from human intestinal EC cells, and also represents the first investigation of primary
colonic EC cells with regards to nutrient sensing. Our findings support the existence of a distinct
glucose-sensing pathway in colonic EC cells (that may co-exist in proximal cells) that, based on the
lack of response to αMG, appears to require glucose metabolism.
Mounting evidence indicates that peripheral 5-HT production and bioavailability is increased in
obesity. Expression of TPH1 [23,24] and PAX4 (a critical transcription factor in EC cell specification) [23]
is augmented in the duodenum and gastric antrum of obese subjects, while levels of plasma 5-HT and
serum levels of the 5-HT metabolite, 5-HIAA, are associated with measures of human obesity [24,34].
Rodent models of obesity also show increased EC cell density (per unit area) and 5-HT content, which
precedes obesity, as well as augmented plasma 5-HT [21–23]. Indeed, peripheral pharmacological
blockade or genetic disruption of TPH is protective against obesity and the development of diabetes
in high fat diet-fed mice [20,25], highlighting a role for peripheral 5-HT in obesogenic processes.
We recently reported that obese subjects have an augmented capacity to release gut derived serotonin
in response to duodenal glucose infusion, relative to non-obese subjects (males and females) [24]. No
differences in glucose sensitivity (proportion of EC cells activated by glucose) or cellular 5-HT content
in isolated primary duodenal EC cells were observed, indicating that increased EC cell density was
the main cause of the increased gut-5-HT capacity. Together with findings above, those findings are
consistent with the view that increased EC cell density and tissue releasable 5-HT, rather than increases
in cellular 5-HT content, augment circulating 5-HT in obesity.
Here we have investigated whether the capacity of EC cells to secrete 5-HT in response to glucose
varies in relation to sex and BMI. We revealed that while colonic EC cells had similar content and
glucose-evoked 5-HT release, duodenal EC cells in overweight females had higher 5-HT content than
lean or obese, and augmented glucose-evoked 5-HT release compared to obese. In addition, while
duodenal EC cells from lean and obese male subjects responded to glucose, glucose-evoked 5-HT
release was not apparent in overweight male subjects.
An explanation for the increased capacity of the duodenal 5-HT system in overweight females
may be that metabolic influences that demand and increase gut 5-HT in overweight individuals are
mitigated through increases in EC cell density in established obesity. To this end, it is known that 5-HT
synthesis in pancreatic islets is increased, and augments insulin secretion, for the metabolic demands
of pregnancy [35] or in response to a high-fat diet [36]. The decreased glucose-evoked sensitivity of
glucose-evoked 5-HT release in the duodenum of overweight and obese females may be a similar
phenomenon to that occurring in pancreatic beta cells of individuals with type 2 diabetes. While
the physiological ramifications of the loss of glucose sensitivity in these cohorts is unclear, it could
potentially affect local 5-HT effects on chloride secretion and gut motility in response to nutrient
ingestion. One possibility may be that metabolic influences that demand and increase gut 5-HT in
overweight individuals are mitigated through increases in EC cell density in established obesity.
Increased intestinal 5-HT outputs in females may have implications not only for the endocrine
effects of 5-HT on metabolism [37], but also for gut paracrine 5-HT signalling. Relatively small amounts
of 5-HT are released from guinea-pig primary colonic EC cell vesicles per exocytic event [38–41] and
acute exposure to high glucose (100 nM) increases the amount of serotonin released per fusion event,
without affecting the frequency of exocytic events [10]. The amount released per fusion event is dictated
by several factors, including vesicle loading. Increased 5-HT vesicle loading will augment activation
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of adjacent 5-HT receptors on afferent nerve terminals [26], which may, correspondingly, increase
gut motility and slow gastric emptying. Interestingly, many patients with gastroparesis, a condition
associated with markedly slowed or incomplete gastric emptying, are overweight females [42]. Our
findings of increased 5-HT synthesis in EC cells from overweight females offer a potential explanation
for the sex bias in gastroparesis, via a mechanism involving downstream 5-HT signalling effects on gut
motility and/or vagal activation.
We observed lower glucose-evoked 5-HT release in obese compared to overweight females.
While rodent and human studies provide evidence of increased gut derived 5-HT in obesity (as
described above), a loss of luminal glucose-evoked 5-HT release has been identified as an early
event in diet-induced obesity in rats [43]. Specific reduction in EC cell glucose-evoked 5-HT output
(compared to overweight, but not too lean) in obese female (human) subjects has not been previously
described. Sex-specific differences in intestinal 5-HT physiology exist in rodents, with higher EC
cell density and increased jejunal 5-HT availability reported in female mice, and a male-specific
impairment of SERT-mediated 5-HT reuptake in the small intestine in diet-induced obesity [21,44].
Evidence suggests that this impairment of SERT is accompanied by an upregulation of the dopamine
transporter (DAT) [44]. In our study, duodenal EC cells did not show glucose-dependent 5-HT release
in overweight males. Whilst a SERT inhibitor was used in our assays to prevent serotonin reuptake,
we cannot exclude the possibility of reuptake via DAT.
Due to the opportunistic nature of specimen acquisition, we did not collect information on the
hormonal status of female patients, which should be investigated using a more targeted approach
in future studies. However, levels of plasma sex hormones estradiol, progesterone and testosterone,
were unaffected by high-fat diet feeding in mice that exhibited sex-biased differences in serotonergic
homeostasis [44]. The sex-specific nature of these mechanisms in humans requires further study.
5. Conclusions
In conclusion, we showed that primary human EC cells secrete 5-HT in response to meal-related
luminal concentrations of glucose, with BMI and region dependent variability in 5-HT content and
output in females. Broader selectivity for sugars in the proximal intestine supports the presence of
multiple sensing pathways, whilst glucose specificity in the distal intestine raises the possibility
of previously uncharacterised glucose sensing mechanism(s). Future research should focus on
investigating the cellular mechanisms of glucose sensing and stimulus-secretion pathways in human
EC cells. Understanding the drivers behind EC cell 5-HT synthesis, and release in overweight females,
and its physiological relevance, will provide new insight into the expanding roles of gut 5-HT in health
and disease.
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